$54.09
1.55%
Downside
Day's Volatility :5.52%
Upside
4.03%
51.97%
Downside
52 Weeks Volatility :76.44%
Upside
50.94%
Period | Cytokinetics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 2.46% | 5.1% | 0.0% |
6 Months | -17.85% | 4.9% | 0.0% |
1 Year | 47.75% | 16.6% | 0.0% |
3 Years | 74.2% | 13.2% | -22.3% |
Market Capitalization | 6.6B |
Book Value | $0.92 |
Earnings Per Share (EPS) | -5.36 |
PEG Ratio | -0.42 |
Wall Street Target Price | 80.65 |
Profit Margin | 0.0% |
Operating Margin TTM | -52277.91% |
Return On Assets TTM | -27.46% |
Return On Equity TTM | -572.15% |
Revenue TTM | 3.1M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | -71.3% |
Gross Profit TTM | -146.2M |
EBITDA | -493.2M |
Diluted Eps TTM | -5.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.18 |
EPS Estimate Next Year | -4.9 |
EPS Estimate Current Quarter | -1.06 |
EPS Estimate Next Quarter | -1.09 |
What analysts predicted
Upside of 49.1%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 31.5M | ↑ 135.64% |
Net Income | -106.3M | ↓ 16.83% |
Net Profit Margin | -337.41% | ↑ 618.53% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.9M | ↓ 14.71% |
Net Income | -149.1M | ↑ 40.23% |
Net Profit Margin | -554.76% | ↓ 217.35% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 55.8M | ↑ 107.79% |
Net Income | -164.1M | ↑ 10.12% |
Net Profit Margin | -294.0% | ↑ 260.76% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 70.4M | ↑ 26.15% |
Net Income | -242.4M | ↑ 47.67% |
Net Profit Margin | -344.14% | ↓ 50.14% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 94.6M | ↑ 34.3% |
Net Income | -402.6M | ↑ 66.09% |
Net Profit Margin | -425.58% | ↓ 81.44% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 7.5M | ↓ 92.04% |
Net Income | -526.2M | ↑ 30.73% |
Net Profit Margin | -7.0K% | ↓ 6563.05% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.6M | ↑ 135.72% |
Net Income | -129.4M | ↓ 1.54% |
Net Profit Margin | -2.8K% | ↑ 3911.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 867.0K | ↓ 81.21% |
Net Income | -128.6M | ↓ 0.62% |
Net Profit Margin | -14.8K% | ↓ 12031.02% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 378.0K | ↓ 56.4% |
Net Income | -129.4M | ↑ 0.61% |
Net Profit Margin | -34.2K% | ↓ 19401.6% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7M | ↑ 342.33% |
Net Income | -136.9M | ↑ 5.77% |
Net Profit Margin | -8.2K% | ↑ 26051.06% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 835.0K | ↓ 50.06% |
Net Income | -135.6M | ↓ 0.92% |
Net Profit Margin | -16.2K% | ↓ 8057.11% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 249.0K | ↓ 70.18% |
Net Income | -143.3M | ↑ 5.66% |
Net Profit Margin | -57.6K% | ↓ 41312.76% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 211.2M | ↓ 28.37% |
Total Liabilities | 185.2M | ↑ 0.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 289.8M | ↑ 37.24% |
Total Liabilities | 300.8M | ↑ 62.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 533.8M | ↑ 84.19% |
Total Liabilities | 420.4M | ↑ 39.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 841.3M | ↑ 57.61% |
Total Liabilities | 597.5M | ↑ 42.11% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 20.62% |
Total Liabilities | 1.1B | ↑ 87.91% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 824.3M | ↓ 18.77% |
Total Liabilities | 1.2B | ↑ 7.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 889.8M | ↓ 12.31% |
Total Liabilities | 1.1B | ↓ 0.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 779.9M | ↓ 12.35% |
Total Liabilities | 1.1B | ↓ 0.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 740.6M | ↓ 5.04% |
Total Liabilities | 1.2B | ↑ 5.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 824.3M | ↑ 11.3% |
Total Liabilities | 1.2B | ↑ 2.65% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 808.1M | ↓ 1.97% |
Total Liabilities | 1.2B | ↓ 0.53% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 88.57% |
Total Liabilities | 1.4B | ↑ 17.52% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -101.2M | ↓ 0.53% |
Investing Cash Flow | 5.1M | ↓ 107.8% |
Financing Cash Flow | 13.1M | ↓ 94.19% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -90.9M | ↓ 10.18% |
Investing Cash Flow | -74.7M | ↓ 1555.43% |
Financing Cash Flow | 159.8M | ↑ 1116.81% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.9M | ↓ 109.84% |
Investing Cash Flow | -196.5M | ↑ 163.05% |
Financing Cash Flow | 234.1M | ↑ 46.52% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -142.5M | ↓ 1693.67% |
Investing Cash Flow | -147.8M | ↓ 24.8% |
Financing Cash Flow | 320.0M | ↑ 36.67% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -299.5M | ↑ 110.15% |
Investing Cash Flow | -262.1M | ↑ 77.38% |
Financing Cash Flow | 516.2M | ↑ 61.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -122.3M | ↑ 24.54% |
Investing Cash Flow | 165.5M | ↑ 465.82% |
Financing Cash Flow | -7.2M | ↓ 124.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -121.8M | ↓ 0.39% |
Investing Cash Flow | 82.1M | ↓ 50.37% |
Financing Cash Flow | 5.5M | ↓ 176.29% |
Sell
Neutral
Buy
Cytokinetics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cytokinetics Inc | 5.6% | -17.85% | 47.75% | 74.2% | 326.91% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cytokinetics Inc | NA | NA | -0.42 | -5.18 | -5.72 | -0.27 | NA | 0.92 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cytokinetics Inc | Buy | $6.6B | 326.91% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cytokinetics Inc
Revenue is down for the last 3 quarters, 1.67M → 249.0K (in $), with an average decrease of 60.1% per quarter
Netprofit is down for the last 2 quarters, -135.64M → -143.31M (in $), with an average decrease of 5.7% per quarter
BlackRock Inc
Vanguard Group Inc
FMR Inc
T. Rowe Price Investment Management,Inc.
Wellington Management Company LLP
Bank of America Corp
Cytokinetics Inc’s price-to-earnings ratio stands at None
Read Morecytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Organization | Cytokinetics Inc |
Employees | 423 |
CEO | Mr. Robert I. Blum |
Industry | Health Technology |
Assetmark Financial Holdings Inc
$54.09
-3.29%
Fidelity Msci Health Care Etf
$54.09
-3.29%
Texas Capital Bancshares Inc.
$54.09
-3.29%
Primerica, Inc.
$54.09
-3.29%
Thor Industries Inc.
$54.09
-3.29%
Qifu Technology Inc
$54.09
-3.29%
Crinetics Pharmaceuticals Inc
$54.09
-3.29%
Hercules Capital Inc
$54.09
-3.29%
Janus Henderson Mortgage-backed Securities Etf
$54.09
-3.29%